[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022

Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follicular lymphoma) andTecentriq (early-stage lung cancer); EU marketing authorisation application submitted forglofitamab (blood cancer)US approval ofEvrysdi (babies under two months of age with spinal muscular atrophy) and US priority review forLunsumioLaunch of innovative platforms and systems for tissue-based cancer diagnostics, of HPV self-sampling solution and monkeypox virus test kitsOutlook for 2022 confirmedRoche CEO Severin Schwan: “We achieved good results in the first half of the year, thanks to the continued strong demand for our diagnostics base business and our new medicines to treat haemophilia, cancer and neurological disorders. Thanks to the ongoing renewal of our portfolio, we continue to grow despite biosimilars, w hose impact declined further as expected. Based on our current assessment, we confirm the outlook for the full year.”Key figuresCHF millions% cha...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Actemra | Activase | African Health | Age-Related Macular Degeneration (AMD) | Alfalfa | Allergy & Immunology | Alzheimer's | Appendicitis | Arthritis | Asthma | Autoimmune Disease | Avastin | Babies | Biotechnology | Bladder Cancer | Brain | Brain Cancers | Brain Tumor | Breast Cancer | Canada Health | Cancer | Cancer & Oncology | Cervical Cancer | Chemistry | Chemotherapy | Child Development | Children | China Health | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Colombia Health | Colorectal Cancer | COVID-19 | Diabetes | Diabetes Type 1 | Emergency Medicine | Endocrinology | Epidemiology | European Medicines Agency (EMA) | Eyes | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Genital Warts | Germany Health | Government | Haemophilia | Hemophilia | Hepatitis | Hepatitis C | HER2 | Herceptin | History of Medicine | Hives | HPV Testing | Human Papillomavirus (HPV) | Immunotherapy | India Health | Information Technology | International Medicine & Public Health | Italy Health | Japan Health | Leukemia | Liver | Lucentis | Lung Cancer | Lymphoma | Marketing | Men | Middle East Health | Monkeypox | Multiple Sclerosis | Muscular Dystrophy | Myasthenia Gravis | Neurology | Neuroscience | Neurosurgery | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries | Partnerships | Pathology | PET Scan | Pharmaceuticals | Pneumonia | Primary CNS Lymphoma | Profits and Losses | Pulmozyme | Ranibizumab Injection | Reflex Sympathetic Dystrophy | Rheumatoid Arthritis | Rheumatology | Rituxan | Russia Health | SARS | Science | Spain Health | Spinal Muscular Atrophy | Statistics | Study | Switzerland Health | Tuberculosis | Turkey Health | Urology & Nephrology | USA Health | Vasculitis | Women | Xolair